REVIEWS |
|
P.B. Shorokhova, V.L. Baranov, N.V. Vorokhobina, O.S. Shpilevaya
Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
|
10-16 |
|
I.A. Kurnikova, A.Yu. Yurovsky
Diabetic autonomic neuropathy: problems of diagnosis and therapy
|
17-24 |
|
|
Ya.V. Girsh
Insulin detemir and its place in the diabetes treatment: results of 15-year use
|
26-35 |
ORIGINAL ARTICLES |
|
M.B. Antsiferov (1), B.B. Kvasnikov (2)
The first results of an observational retrospective study assessing the effectiveness of the use dapagliflozin in patients with type 2 diabetes mellitus in real clinical practice in the Russian Federation (GLORIA study)
|
36-45 |
|
N.A. Demidov (1), O.A. Mishra (2), M.B. Antsiferov (3)
Experience of the use of insulin degludec in the treatment of patients with type 1 diabetes mellitus (according to the data of the Moscow segment of the Federal Diabetes Register)
|
46-49 |
|
N.S. Alekseeva (1), E.V. Beloborodova (2)
The effectiveness of therapeutic measures in metabolic syndrome and vitamin d deficiency
|
50-54 |
|
G.I. Izhbuldina (1), L.B. Novikova (2)
Hyperglycemia and ischemic stroke: clinical features in patients with type 2 diabetes mellitus
|
56-60 |
|
K.V. Antonova (1), M.M. Tanashyan (1), M.Yu. Maksimova (1), N.V. Shakhparonova (1), T.I. Romantsova (2)
The state of carbohydrate metabolism and the development of cerebrovascular diseases in patients with type 2 diabetes mellitus
|
61-67 |
|
|
F.E. Shadrichev (1, 2), T. Yu. Demidova (3), N.N. Grigorieva (2, 4), A.A. Kozhevnikov (3)
Prevention of blindness in diabetes mellitus. From retinal laser coagulation to pharmacology
|
68-78 |
|
E.G. Starostina
New era of type 2 diabetes mellitus therapy: cardiological indications for the use of glucagon-like peptide-1 receptor agonists
|
79-88 |
|
M.B. Antsiferov (1), O.M. Koteshkova (1), N.A. Demidov (2)
The use of personal systems for continuous monitoring of glycemia in diabetic patients on insulin
|
89-95 |
|
A.P. Pereverzev, O.D. Ostroumova, O.N. Tkacheva
Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia
|
96-99 |
|
M.B. Antsiferov (1), T.M. Alekseeva (1), A.V. Andreeva (2)
Current approaches to the diagnostics and treatment of acromegaly
|
100-104 |
|
L.A. Sharonova, A.F. Verbovoy
The place of glyflozins in the management of type 2 diabetes mellitus
|
105-110 |
|
E.V. Biryukova, I.V. Solovyova
Do we know everything about the possibilities of metformin in the treatment of type 2 diabetes mellitus? Which of its combinations is the most studied, effective and available for the patient in the real practice of the endocrinologist?
|
111-121 |
|
T.N. Markova (1, 2)
Obesity and associated diseases. Modern possibilities of prevention and treatment in real clinical practice
|
122-127 |
|
I.B. Zhurtova (1), S.Kh. Sizhazheva (1), M.Z. Ivanova (2)
Thyrotoxicosis syndrome: difficulties of diagnostics and treatment (case of amyodaron-induced tyreotoxycosis)
|
128-133 |
|
A.E. Goldshmid (1), E.Yu. Martynova (1), Yu.E. Poteshkin (2)
Clinical case of the use of the long-acting somatostatin analogue in a patient with acromegaly who has not achieved clinical and laboratory remission after telegrammatherapy
|
134-137 |
Resolution |
|
Extreme risk category in the stratification of cardiovascular complications. Consensus Council of experts
|
138-143 |
Русский
